Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Terrassa – page 121

3 744 clinical trials in Terrassa, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Terrassa at a glance
3 744
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

3 744 trials in Terrassa

Open in trial search

Mite allergy

Not yet recruiting

Efficacy and safety of house dust mite allergoid (Dermatophagoides farinae, D. pteronyssinus, aluminium hydroxide) in people with moderate to severe house dust mite allergy

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Aluminium Hydroxide
  • Sponsor:Allergopharma GmbH & Co. KG

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Therakos Europe Limited

Retinal dystrophy

Not yet recruiting

A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ziloretgene parvec
  • Sponsor:Atsena Therapeutics Inc.

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Study of dapirolizumab pegol placental transfer to infants in pregnant women with active systemic lupus erythematosus (drug combination)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Benzocaine
  • Sponsor:UCB Biopharma

Ovarian cancer

Not yet recruiting

Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Sickle cell disease

Not yet recruiting

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Osteosarcoma+2

Not yet recruiting

A Randomized Study of Trabectedin With Low‑Dose Radiotherapy Versus Trabectedin Alone in Adults With Advanced Soft Tissue Sarcoma, Osteosarcoma, or Ewing Sarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trabectedin
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Safety and Immune Response of GBS‑NN/NN2 Vaccine in Pregnant Women and Their Infants to Prevent Group B Streptococcus Infection

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:GBS-NN
  • Sponsor:Minervax ApS

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Celea Therapeutics Inc.

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Terrassa

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, breast cancer, and prostate cancer treatments. Innovative combination therapies and targeted approaches are being evaluated for improved patient outcomes.

  • Gastrectomy procedures for cancer treatment
  • HER2-positive breast cancer therapies
  • Advanced prostate cancer management

Studies include novel immunotherapy combinations and precision medicine approaches.

02 Immunology and Allergies

Clinical trials investigating immunotherapy treatments for various allergic conditions, including advanced research in rhinitis and rhinoconjunctivitis management.

  • House dust mite allergies
  • Cupressaceae pollen sensitivity
  • Combined allergy treatments

Focus on developing targeted allergen-specific treatments for improved quality of life.

03 Neurology and Mental Health

Innovative research into Parkinson's Disease and Alzheimer's Disease, exploring new therapeutic approaches and disease-modifying treatments.

  • Early-stage Alzheimer's interventions
  • Parkinson's Disease management
  • Seizure control therapies

Studies emphasize long-term safety and efficacy of novel therapeutic agents.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.